MS
ALLO icon

Murray Stahl’s Allogene Therapeutics ALLO Stock Holding History

Murray Stahl’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.9K Sell
16,776
-806
-5% -$1.77K ﹤0.01% 334
2026
Q1 		$42.9K Sell
17,582
-806
-4% -$1.62K ﹤0.01% 337
2025
Q4 		$25.2K Sell
18,388
-806
-4% -$1.06K ﹤0.01% 320
2025
Q3 		$23.8K Buy
19,194
+806
+4% +$961 ﹤0.01% 333
2025
Q2 		$20.8K Sell
18,388
-806
-4% -$1.07K ﹤0.01% 347
2025
Q1 		$28K Hold
19,194
– – ﹤0.01% 342
2024
Q4 		$40.9K Buy
19,194
+806
+4% +$1.99K ﹤0.01% 342
2024
Q3 		$51.5K Sell
18,388
-806
-4% -$2.15K ﹤0.01% 337
2024
Q2 		$44.7K Hold
19,194
– – ﹤0.01% 319
2024
Q1 		$85.8K Hold
19,194
– – ﹤0.01% 312
2023
Q4 		$61.6K Sell
19,194
-806
-4% -$2.29K ﹤0.01% 314
2023
Q3 		$63.4K Hold
20,000
– – ﹤0.01% 320
2023
Q2 		$99.4K Hold
20,000
– – ﹤0.01% 319
2023
Q1 		$98.8K Buy
+20,000
New +$128K ﹤0.01% 320

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Murray Stahl's ALLO Position: Q2 2026 in Review

Murray Stahl reduced its Allogene Therapeutics (ALLO) stake by 4.6% in Q2 2026, selling an estimated $1.77K and leaving 16,776 shares worth $34.9K. The position accounts for ﹤0.01% of the portfolio, ranked #334.

Murray Stahl first reported a position in ALLO in Q1 2023 and has held it in 14 quarters since. The position peaked at $99.4K in Q2 2023. 207 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Murray Stahl held 16,776 shares of Allogene Therapeutics worth $34.9K as of Q2 2026.
  • Murray Stahl sold 806 Allogene Therapeutics shares in Q2 2026, an estimated $1.77K.
  • Allogene Therapeutics made up ﹤0.01% of Murray Stahl's portfolio in Q2 2026, its #334 holding.
  • Murray Stahl first reported a position in Allogene Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Murray Stahl's Allogene Therapeutics position peaked at $99.4K in Q2 2023.
  • 207 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.